Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

Stage 1: Inclusion Criteria: * 1\. Aged 18 to 80 years, either sex; * 2\. Patients with histologically or cytologic confirmed advanced solid tumors should have failed the standard treatment, or have no standard treatment regimen available, or have no access to standard treatment; * 3\. Tumor tissue samples is CLDN18.2 positive; * 4\. According to RECIST1.1, there are at least one evaluable tumor lesion during dose escalation period (stage 1), and at least one measurable tumor lesion during dose expansion period (stage 2); * 5\. The ECOG score is 0 to 1; * 6\. Expected survival \> 3 months; * 7\. Various organs in good condition; * 8\. Fertile eligible patients (male and female) and their partners are willing to use a reliable method of contraception (hormones, barriers or abstinence) during the study and within 90 days after the last study treatment; women of childbearing potential must be tested for serum or urine pregnancy within 7 days before enrollment with negative results; * 9\. Patients are informed of this study before the trial and sign written informed consent form. Exclusion Criteria: * 1\. Received anti-tumor therapies within 4 weeks prior to first administration of study drug, except: within 6 weeks for nitrosoureas or mitomycin C, within 2 weeks or 5 half-life of drugs (whichever longer) for oral fluorouracils and small molecular targeted drugs, and within 2 weeks for traditional Chinese medicines with indications of anti-tumor; * 2\. Received other non-mark…